Sunyoung Jang1, Oluseye Ogunmoroti1, Di Zhao1,2, Oluwaseun E Fashanu3, Martin Tibuakuu1, Eve-Marie Benson2, Faye Norby4, James D Otvos5, Susan R Heckbert6, Moyses Szklo2, Erin D Michos1,2. 1. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. 3. Department of Medicine, Saint Agnes Hospital, Baltimore, Maryland, United States of America. 4. Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota, United States of America. 5. Laboratory Corporation of America Holdings, Morrisville, North Carolina, United States of America. 6. Department of Epidemiology, University of Washington, Seattle, Washington, United States of America.
Abstract
BACKGROUND: Emerging evidence has implicated that inflammation contributes to the pathogenesis of atrial fibrillation (AF). GlycA is a novel marker of systemic inflammation with low intra-individual variability and high analytic precision. GlycA has been associated with incident cardiovascular disease (CVD) independent of other inflammatory markers. However, whether GlycA is associated with AF, specifically, has yet to be established. We examined the association between GlycA and AF in a multi-ethnic cohort. METHODS: We studied 6,602 MESA participants aged 45-85, with no clinical CVD at baseline, with data on GlycA and incident AF. We used multivariable-adjusted Cox models to evaluate the association between GlycA and incident AF. We also examined other inflammatory markers [high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL6) and fibrinogen] and incident AF for comparison. RESULTS: The mean (SD) age was 62 (10) years, 53% women. The mean plasma GlycA was 381 (62) μmol/L. Over median follow-up of 12.9 years, 869 participants experienced AF. There was no statistically significant association between GlycA and incident AF after adjusting for sociodemographics, CVD risk factors, and other inflammatory markers [Hazard Ratio (95% CI) per 1 SD increment in GlycA: 0.97 (0.88-1.06)]. Neither hsCRP nor fibrinogen was associated with incident AF in same model. In contrast, IL-6 was independently associated with incident AF [HR 1.12 per 1 SD increment (1.05-1.19)]. CONCLUSIONS: Although GlycA has been associated with other CVD types, we found that GlycA was not associated with AF. More research will be required to understand why IL-6 was associated with AF but not GlycA. CLINICAL TRIAL REGISTRATION: MESA is not a clinical trial. However, the cohort is registered at: URL: https://clinicaltrials.gov/ct2/show/NCT00005487 Unique identifier: NCT00005487.
BACKGROUND: Emerging evidence has implicated that inflammation contributes to the pathogenesis of atrial fibrillation (AF). GlycA is a novel marker of systemic inflammation with low intra-individual variability and high analytic precision. GlycA has been associated with incident cardiovascular disease (CVD) independent of other inflammatory markers. However, whether GlycA is associated with AF, specifically, has yet to be established. We examined the association between GlycA and AF in a multi-ethnic cohort. METHODS: We studied 6,602 MESAparticipants aged 45-85, with no clinical CVD at baseline, with data on GlycA and incident AF. We used multivariable-adjusted Cox models to evaluate the association between GlycA and incident AF. We also examined other inflammatory markers [high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL6) and fibrinogen] and incident AF for comparison. RESULTS: The mean (SD) age was 62 (10) years, 53% women. The mean plasma GlycA was 381 (62) μmol/L. Over median follow-up of 12.9 years, 869 participants experienced AF. There was no statistically significant association between GlycA and incident AFafter adjusting for sociodemographics, CVD risk factors, and other inflammatory markers [Hazard Ratio (95% CI) per 1 SD increment in GlycA: 0.97 (0.88-1.06)]. Neither hsCRP nor fibrinogen was associated with incident AF in same model. In contrast, IL-6 was independently associated with incident AF [HR 1.12 per 1 SD increment (1.05-1.19)]. CONCLUSIONS: Although GlycA has been associated with other CVD types, we found that GlycA was not associated with AF. More research will be required to understand why IL-6 was associated with AF but not GlycA. CLINICAL TRIAL REGISTRATION: MESA is not a clinical trial. However, the cohort is registered at: URL: https://clinicaltrials.gov/ct2/show/NCT00005487 Unique identifier: NCT00005487.
Authors: Angelica Ezeigwe; Oluwaseun E Fashanu; Di Zhao; Matthew J Budoff; James D Otvos; Isac C Thomas; Samia Mora; Martin Tibuakuu; Erin D Michos Journal: Atherosclerosis Date: 2019-01-24 Impact factor: 5.162
Authors: David G Harrison; Tomasz J Guzik; Heinrich E Lob; Meena S Madhur; Paul J Marvar; Salim R Thabet; Antony Vinh; Cornelia M Weyand Journal: Hypertension Date: 2010-12-13 Impact factor: 10.190
Authors: Sarah C W Marott; Børge G Nordestgaard; Jeppe Zacho; Jens Friberg; Gorm B Jensen; Anne Tybjaerg-Hansen; Marianne Benn Journal: J Am Coll Cardiol Date: 2010-08-31 Impact factor: 24.094
Authors: James D Otvos; Irina Shalaurova; Justyna Wolak-Dinsmore; Margery A Connelly; Rachel H Mackey; James H Stein; Russell P Tracy Journal: Clin Chem Date: 2015-03-16 Impact factor: 8.327
Authors: Angelica Ezeigwe; Oluseye Ogunmoroti; Anum S Minhas; Carla P Rodriguez; Brigitte Kazzi; Oluwaseun E Fashanu; Olatokunbo Osibogun; Lara C Kovell; Colleen M Harrington; Erin D Michos Journal: Front Cardiovasc Med Date: 2022-09-14